Oral Testosterone Undecanoate Formulation with PPARα Agonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current testosterone replacement therapies for treating testosterone deficiency are inadequate due to poor bioavailability, ineffective pharmacokinetics, and adverse effects such as liver toxicity, skin irritation, and cardiovascular risk associated with HDL suppression, with no approved oral formulations of testosterone esters available.
Innovation Solution
A pharmaceutical product combining testosterone undecanoate with a hypolipidemic agent, specifically a PPARα agonist, to enhance serum testosterone levels and HDL particle concentrations, utilizing a solubilization system with lipophilic and hydrophilic surfactants to improve absorption and maintain stable plasma concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If testosterone esters with long carbon chains are used to improve absorption via intestinal lymphatics, then first pass metabolism is reduced, but the rate and extent of hydrolysis by esterases decreases resulting in poor pharmacological activity
Solution Approach 1:
The patent changes the carbon chain length parameter of the testosterone ester to an optimal range (10-14 carbons) that balances lymphatic absorption capability with hydrolysis rate. This parameter optimization resolves the contradiction by finding the sweet spot where both absorption and pharmacological activity are sufficient.
Solution Approach 2:
The patent introduces formulation excipients and solubilization systems as intermediaries to enhance the solubility and stability of testosterone esters in the gastrointestinal environment. These intermediaries facilitate better absorption without requiring excessively long carbon chains, thereby maintaining hydrolysis efficiency.
2Ease of operation
If testosterone and testosterone esters are administered orally, then convenience is improved, but extensive first pass intestinal and hepatic metabolism results in poor bioavailability
Solution Approach 1:
The patent modifies the ester chain length parameter to optimize the balance between oral bioavailability and pharmacological effectiveness. By selecting esters with 10-14 carbon chains, the formulation achieves sufficient survival through first-pass metabolism while maintaining adequate hydrolysis to release active testosterone.
Solution Approach 2:
The patent employs formulation excipients, solubilizing agents, and protective matrices as intermediaries to shield the testosterone ester from premature metabolism during oral passage. These intermediaries enhance bioavailability by protecting the drug through the gastrointestinal tract and first-pass metabolism.
3Quantity of substance
If testosterone replacement therapy is administered, then serum testosterone levels are increased, but HDL cholesterol levels are suppressed increasing cardiovascular risk
Solution Approach 1:
The patent employs partial action by using physiological doses of testosterone esters that achieve adequate replacement levels without excessive supraphysiological elevation. This approach maintains testosterone benefits while minimizing the excessive HDL suppression that occurs with higher doses.
Solution Approach 2:
The patent introduces hypolipidemic agents as intermediaries that counterbalance the HDL-lowering effect of testosterone therapy. These agents work alongside testosterone replacement to maintain lipid profile stability, thereby reducing cardiovascular risk while preserving testosterone benefits.
4Reliability
If testosterone esters are solubilized in aqueous media for absorption, then gastrointestinal absorption is improved, but the testosterone ester precipitates out of solution in vivo
Solution Approach 1:
The patent employs solubilizing excipients, surfactants, and cosolvents as intermediaries that maintain testosterone ester solubility throughout the gastrointestinal tract and into systemic circulation. These intermediaries prevent precipitation by reducing interfacial tension and stabilizing the drug in aqueous environments.
Solution Approach 2:
The patent creates composite formulations combining testosterone esters with multiple excipients, surfactants, and solubilizing agents that work synergistically. This composite approach ensures both initial solubilization for absorption and sustained stability to prevent precipitation in vivo.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination provides sustained and clinically effective serum testosterone levels with minimal diurnal variation, reduced HDL suppression, and enhanced cardiovascular safety by increasing anti-atherogenic HDL particles, thereby addressing the limitations of existing therapies.
Implementation Method 1
utilizing a solubilization system with lipophilic and hydrophilic surfactants to improve absorption
Implementation Method 2
a hypolipidemic agent that increases the plasma concentration of one or more HDL particle subclasses in an individual; specifically a PPARα agonist
Data Source
AI summary
Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.